Daiichi/Lilly’s Prasugrel Overcomes Cancer Hurdle, Receives Favorable Panel Recommendation

The frequency of cancer tumors seen in the prasugrel arm of Lilly/Daiichi Sankyo's TRITON trial was not enough to seriously concern a U.S. FDA advisory committee as the panel voted unanimously to recommend approval of the platelet inhibitor